Kennedy Adds To List Of Follow-On Biologics Bills

Law360, New York (July 8, 2009, 12:00 AM EDT) -- Adding to several bills seeking a regulatory pathway for approval of follow-on versions of biologic drugs, Sen. Edward Kennedy, D-Mass., has reportedly put in his own proposal that would allow drugmakers to secure up to 13.5 years of protection on brand-name biologic drugs before a follow-on version could enter the market.

Kennedy, chairman of the Senate Health Committee, introduced legislation Tuesday that would give drugmakers between 12 and 13.5 years of exclusivity to sell their biologics, which are protein products in living cells, before a biosimilar...
To view the full article, register now.